Haematologica

Papers
(The TQCC of Haematologica is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Pediatric acute lymphoblastic leukemia259
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy194
International recommendations on the diagnosis and treatment of acquired hemophilia A176
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia97
Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia93
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma89
One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors88
Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial84
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens76
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia74
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma74
Multiple myeloma: the (r)evolution of current therapy and a glance into future71
Acquired von Willebrand syndrome: focused for hematologists70
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models70
Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion64
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide63
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition62
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study61
History of hematopoietic cell transplantation: challenges and progress60
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT58
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study58
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE t57
Geriatric assessment in older patients with a hematologic malignancy: a systematic review55
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria55
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis53
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia51
Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies50
Complement C5 inhibition in patients with COVID-19 - a promising target?50
Myelodysplastic syndromes: moving towards personalized management48
A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies48
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients47
Post-mortem findings in vaccine-induced thrombotic thombocytopenia47
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma46
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies46
ABO blood groups are not associated with risk of acquiring the SARS-CoV-2 infection in young adults46
VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome)44
MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma44
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma44
Inherited thrombocytopenias: history, advances and perspectives43
Potential targeting of FLT3 acute myeloid leukemia43
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL191343
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression43
Targeting the tumor microenvironment in chronic lymphocytic leukemia43
Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance43
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk42
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome42
miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis41
The interactome of the N-terminus of band 3 regulates red blood cell metabolism and storage quality41
Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS40
Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients39
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells38
Red cell transfusion and alloimmunization in sickle cell disease37
Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021?37
Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany37
Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy37
A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis35
<i>In vitro</i> and <i>in vivo</i> induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor35
Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial35
<i>DUX4r</i>, <i>ZNF384r</i> and <i>PAX5</i>-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch34
Complement dysregulation is associated with severe COVID-19 illness34
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome34
Leukemic stem cells and therapy resistance in acute myeloid leukemia34
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies33
Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York33
Multiple myeloma with central nervous system relapse33
Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines33
The molecular basis for the prothrombotic state in sickle cell disease33
Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood s33
A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol33
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas32
Unique ethnic features of <I>DDX41</I> mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia32
Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis31
No evidence of hemoglobin damage by SARS-CoV-2 infection31
Maintenance therapy for <i>FLT3-ITD</i>-mutated acute myeloid leukemia31
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation31
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape30
Molecular heterogeneity of pyruvate kinase deficiency30
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma29
The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia29
To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia29
Hemostatic alterations in COVID-1929
IgM monoclonal gammopathies of clinical significance: diagnosis and management29
Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy28
Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding28
COVID-19 and sickle cell disease28
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia28
The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy28
Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma28
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?27
Molecular and phenotypic diversity of <I>CBL</I>-mutated juvenile myelomonocytic leukemia27
COVID-19 in patients with sickle cell disease - a case series from a UK Tertiary Hospital27
Circulating histones play a central role in COVID-19-associated coagulopathy and mortality27
The clinical impact of the molecular landscape of acute myeloid leukemia27
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma27
The variable manifestations of disease in pyruvate kinase deficiency and their management27
Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease26
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leuke26
Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter 26
Successful pregnancies after transplantation of ovarian tissue retrieved and cryopreserved at time of childhood acute lymphoblastic leukemia – A case report25
Mortality in children with sickle cell disease in mainland France from 2000 to 201525
Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia25
Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways25
Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect25
Beta thalassemia minor is a beneficial determinant of red blood cell storage lesion24
Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome24
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study24
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis24
Endothelial damage and dysfunction in acute graft-versus-host disease24
Dramatic presentation of acquired thombotic thrombocytopenic purpura associated with COVID-1924
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study23
Stored blood has compromised oxygen unloading kinetics that can be normalized with rejuvenation and predicted from corpuscular side-scatter23
BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy23
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome23
Ddx41 inhibition of DNA damage signaling permits erythroid progenitor expansion in zebrafish23
Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies23
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute l23
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study23
Aging of human hematopoietic stem cells is linked to changes in Cdc42 activity22
The present and future of measurable residual disease testing in acute myeloid leukemia22
DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study22
Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma22
Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease22
Novel immunotherapies in multiple myeloma – chances and challenges22
Treatment of drug-induced immune thrombocytopenias22
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde22
Impaired microRNA processing in neutrophils from rheumatoid arthritis patients confers their pathogenic profile. Modulation by biological therapies22
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study21
Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia21
Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies21
XPO1 regulates erythroid differentiation and is a new target for the treatment of β-thalassemia21
Marginal zone lymphoma: present status and future perspectives21
CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients21
A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia21
CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity20
Replication stress signaling is a therapeutic target in myelodysplastic syndromes with splicing factor mutations20
Comparison of CD38 antibodies <i>in vitro</i> and <i>ex vivo</i> mechanisms of action in multiple myeloma20
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study20
Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease20
Deregulation of JAK2 signaling underlies primary cutaneous CD8<sup>+</sup> aggressive epidermotropic cytotoxic T-cell lymphoma20
Translational and clinical advances in acute graft-versus-host disease20
<i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)20
Whole exome sequencing identifies mutational signatures of vitreoretinal lymphoma20
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag19
Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis19
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia19
Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype19
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma19
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia19
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades19
Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model19
Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents18
Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients18
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas18
The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis18
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results18
Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis18
The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma18
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies18
Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets18
T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective18
Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia who have been treated with blinatumomab18
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration18
The TRPV2 channel mediates Ca2+ influx and the Δ9-THC-dependent decrease in osmotic fragility in red blood cells18
Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination17
PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia17
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study17
Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation17
Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis17
Prevention and management of secondary central nervous system lymphoma17
Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia17
Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing17
Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing17
Glenzocimab does not impact glycoprotein VI-dependent inflammatory hemostasis17
Characterization of freshly isolated bone marrow mesenchymal stromal cells from healthy donors and patients with multiple myeloma: transcriptional modulation of the microenvironment17
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies17
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an <i>ad hoc</i> expert panel17
Towards manufactured red blood cells for the treatment of inherited anemia17
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome16
Baseline SUV<sub>max</sub> is related to tumor cell proliferation and patient outcome in follicular lymphoma16
The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial16
Dominance of an <i>UBA1</i> mutant clone over a <i>CALR</i> mutant clone: from essential thrombocytemia to VEXAS.16
Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse16
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial16
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study16
Protein-L-isoaspartate O-methyltransferase is required for <i>in vivo</i> control of oxidative damage in red blood cells16
Perforin gene variant A91V in young patients with severe COVID-19.16
The Hsp70 chaperone system: distinct roles in erythrocyte formation and maintenance16
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis16
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation16
IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib16
Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance.16
A frequent nonsense mutation in exon 1 across certain HLA-A and -B alleles in leukocytes of patients with acquired aplastic anemia16
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia15
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project15
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients15
Circulating cell-free <i>BRAF</i> V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis15
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients15
Differentiation therapy of myeloid leukemia: four decades of development15
Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia15
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities15
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients15
Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis- related graft failure and disseminated bacillus Calmette-Guérin infection15
Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature15
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)15
Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia15
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis15
Immune-mediated thrombotic thrombocytopenic purpura following administration of Pfizer-BioNTech COVID-19 vaccine15
Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications15
Crucial role of hematopoietic <i>JAK2</i> V617F in the development of aortic aneurysms15
Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/0615
Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential15
Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications14
Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia14
New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia14
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?14
Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial14
Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia14
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome14
Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia14
Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes14
Post-translational polymodification of β1-tubulin regulates motor protein localization in platelet production and function14
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial14
SARS-CoV-2 infection in aplastic anemia14
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma14
Acute myeloid leukemia shapes the bone marrow stromal niche <i>in vivo</i>14
Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy14
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial14
A novel classification of hematologic conditions in patients with Fanconi anemia14
How I diagnose and treat chronic myelomonocytic leukemia13
Hypoxia-inducible erythropoietin expression: details matter13
Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against <i>FLT3</i>- mutant acute myeloid leukemia and <i>KMT2A</i>-rearranged acute13
Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial13
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma13
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia13
A risk score based on real-world data to predict early death in acute promyelocytic leukemia13
<i>DUSP22</i> rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma13
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study13
Mobilization efficiency is critically regulated by fat via marrow PPARδ13
GNE-related thrombocytopenia: evidence for a mutational hotspot in the ADP/substrate domain of the GNE bifunctional enzyme13
The “7+3” regimen in acute myeloid leukemia13
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study13
The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias13
Mitochondrial ATP generation in stimulated platelets is essential for granule secretion but dispensable for aggregation and procoagulant activity13
Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?13
Prospects in the management of patients with follicular lymphoma beyond first-line therapy13
Time for an individualized approach to first-line management of follicular lymphoma13
Untargeted metabolic profiling in dried blood spots identifies disease fingerprint for pyruvate kinase deficiency13
<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia13
Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma13
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study13
0.053977012634277